Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today confirms that following Admission earlier today of the 25,396,806 Placing Shares, the Amendments to the Convertible Bond as set out in the Placing Announcement have taken effect.
The Company’s enlarged issued ordinary share capital is 436,445,681 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Capitalized terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the Placing Announcement issued on 20 October 2025.